Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
France
In shortOse Immunotherapeutics is loss-making, burns cash and carries moderate debt, with revenue shrinking (−96.3% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -1431.3% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -1439.1% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -82.3% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -49.7% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.28× | 40/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 1.15× | 47/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -12.73× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | – | n/a |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -1299.5% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 1 of 4 | 6/100 |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 4 | 25/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 3 | 44/100 |
| Revenue growth volatility | 147.5% | 0/100 |
| Operating margin volatility | 692.5% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -36.9% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
European data comes from annual reports in ESEF format (since 2020). Industry and ticker are not provided by this source.
Annual figures as reported. Hover a bar or point for the exact value.
The last 4 fiscal years from the company's annual reports.
EUR millions; negative values in parentheses.
| Fiscal year | FY20 | FY21 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | 10 | 26 | 70 | 2.6 |
| Research & development | 22 | 31 | 30 | 34 |
| Operating income | (19) | (17) | 44 | (37) |
| Interest expense | 0.3 | 0.9 | 5.6 | 2.9 |
| Pre-tax income | (19) | (17) | 40 | (37) |
| Income tax | (2.7) | (0.4) | 2.4 | 0.3 |
| Net income | (17) | (17) | 37 | (38) |
| Diluted EPS | −€1.06 | −€0.93 | €1.46 | −€1.69 |
| Diluted shares (millions) | 16 | 18 | 22 | 22 |
Not computed: a required balance-sheet item is missing.
2/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: filings.xbrl.org (ESEF). Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Jun 4, 2026